ClinicalTrials.gg
CompletedNCT03291886Updated Jun 21, 2022

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

A Phase 2 interventional study of Entinostat and Entinostat(Placebo) in Advanced or Recurrent Breast Cancer, sponsored by Kyowa Kirin Co., Ltd.. Completed at 28 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing entinostat in Breast Neoplasms — 4 open to participants now, 6 under way, 1 of them phase 3. entinostat · Breast Neoplasms.

Enrollment
4th of 24
133 · median 54
Started
2017
with 1 other
Phase 2
9 of 24
3 open now
Registered
17th of 24
by date
Lead sponsor
1 of 24
Kyowa Kirin Co., Ltd.

Among the 24 studies testing entinostat in Breast Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 2, and was the 17th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 24 studies testing entinostat in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About entinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing entinostat in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate the effect of 5 mg KHK2375 on progression free survival (PFS) when administered orally at weekly intervals in combination with exemestane in a placebo-controlled, double-blind comparative study in subjects with advanced or recurrent hormone receptor-positive breast cancer. The secondary objectives are to investigate the effect of on overall survival (OS) and the antitumor effect and to evaluate the pharmacokinetics and safety.

03

Conditions studied

  • Advanced or Recurrent Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Personally submitted voluntary written to participate in the study
  2. Age ≥ 20 years at the time of consent
  3. or cytologically confirmed breast cancer positive for estrogen receptor (ER) and/or progesterone receptor (PgR)
  4. Human epidermal growth factor 2 ()-negative
  5. Stage III/locally advanced or carcinoma of the breast where local therapy with curative intent is impossible
  6. Pre/Peri- and women

    • Postmenopausal status is defined either by:

      1. Age ≥ 55 years and ≥ 1 year of amenorrhea
      2. Age \< 55 years and ≥ 1 year of amenorrhea, with blood estradiol (E2) \< 20 pg/mL
      3. Age \< 55 years with hysterectomy, with ovaries and E2 \< 20 pg/mL
    • Surgical menopause with bilateral oophorectomy Pre/perimenopausal women may be enrolled only if they agree to receive an luteinizing hormone-releasing hormone (LH-RH) agonist
  7. (ECOG) performance status (PS) of 0 or 1 at enrollment
  8. Measurable or nonmeasurable lesions per version 1.1 criteria
  9. Subjects meeting either of the following criteria:

    • History of treatment with a nonsteroidal aromatase inhibitor (AI) for advanced or recurrent breast cancer, and development of progressive disease (PD) after the most recent prior treatment
    • No history of treatment with endocrine therapy for advanced or recurrent breast cancer that has recurred during or within 12 months after postoperative therapy with an nonsteroidal AI
  10. An adverse event for which a causal relationship to prior treatment cannot be denied (except alopecia) is Grade ≤ 1 in severity or has returned to the baseline level, i.e., the level before the start of the prior treatment
  11. The latest laboratory values obtained prior to enrollment must meet all of the following requirements:

    • concentration: ≥ 9.0 g/dL
    • count: ≥ 100000/μL
    • : ≥ 1500/μL
    • Serum creatinine: ≤ 2.0 mg/dL
    • Total in serum: \< 1.5 × institutional (≤ 3 mg/dL for subjects with Gilbert's syndrome)
    • (AST) and Alanine transaminase(ALT): ≤ 3.0 × institutional upper limit of normal

Exclusion criteria

Exclusion Criteria:

  1. Endocrine therapy (except for LH-RH agonist), treatment with everolimus, treatment with a cyclin-dependent kinase inhibitor, or radiation therapy within 14 days before enrollment

    Subjects with prior treatment with exemestane may be enrolled if they meet either of the following criteria:

    • Start of treatment with exemestane for advanced or recurrent breast cancer within 28 days before enrollment
    • Recurrence-free period >12 months after completion of treatment with exemestane as postoperative therapy. For painful bone lesions or impending fractures, radiation therapy may be used concomitantly if there is a measurable or nonmeasurable lesion that is suitable for efficacy evaluation in a region other than the radiation field
  2. Two or more prior chemotherapy regimens for advanced or recurrent breast cancer
  3. Chemotherapy within 21 days before enrollment
  4. Treatment with bisphosphonates or anti-RANKL antibody that is scheduled to be started within 7 days before the first dose of product
  5. History of or current central nervous system , or current or periosteal disease
  6. History of cancer other than breast cancer within 5 years, or concurrent cancer other than breast cancer (except for basal cell carcinoma of skin, squamous cell carcinoma of skin, and intraepithelial carcinoma of uterine cervix).Subjects continuing to receive treatment for cancer other than breast cancer are ineligible for enrollment
  7. Ongoing treatment with any other anticancer therapy or investigational product (Except for treatment with exemestane or radiotherapy as described in exclusion criterion 1)
  8. Prior treatment with histone deacetylase inhibitor (e.g. valproate, vorinostat)
  9. Known allergy to imidazoles, exemestane, or entinostat
  10. Any medical or psychiatric condition that could affect compliance with the protocol, ability to give consent, or assessment of anticipated toxicities
  11. Uncontrolled complications (e.g., active infections)
  12. Positive for either surface antigen, virus antibody, or antibody
  13. Any other conditions unsuitable for the study in the opinion of the investigator or subinvestigator
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Arm A (exemestane, Entinostat)

    5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally. Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist.

    Drug: Entinostat · Drug: Exemestane

  • Placebo comparator
    Arm B (exemestane, Entinostat(placebo))

    KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally. Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist.

    Drug: Entinostat(Placebo) · Drug: Exemestane

Interventions

  • Given PO

    Also known as: KHK2375, MS-275, SNDX-275

  • DrugEntinostat(Placebo)

    Given PO

    Also known as: KHK2375, MS-275, SNDX-275

  • Given PO

    Also known as: EXE001, Aromasin, FCE-24304

06

What researchers measure

Primary outcomes

  1. Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)

    PFS is defined as the number of days from the date of randomization to the date of first documented progressive disease (PD) or the date of death from any cause, whichever comes first (date of first documented PD or death - date of randomization + 1). The date of first documented PD is the date when PD is first documented at overall response assessment or the date when overall response other than complete response (CR) and not evaluable (NE) is documented after first CR. Subjects who receive post-study treatment before the documentation of PD and subjects with no documented PD or death will be censored at the last date they were confirmed to have no PD. Subjects whose overall response from the date of randomization onward is only NE or who have never undergone assessment of antitumor effect, and whose death has not been documented will be censored at the date of randomization.

    Time frame: Approximately 29 months

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the number of days from the date of randomization to death from any cause (date of death - date of randomization + 1). Subjects without documented death at the time of data cutoff will be censored at the last date they were confirmed to be alive.

    Time frame: Up to 50 months

  2. Antitumor effect

    The best overall response is defined as the best response recorded from the start of treatment until progression or recurrence according to the categories ordered as CR \> partial response(PR) \> stable disease (SD) \> PD \> NE or CR \> Non-CR/non-PD \> PD \> NE. A best overall response of CR or PR will be regarded as objective response. A best overall response of CR, PR, or SD for at least 6 months will be regarded as clinical benefit.

    Time frame: Up to 50 months

Other outcomes

  1. Plasma concentration of KHK2375

    Time frame: Day 1 of Cycle 1, Day 15 of Cycle 1 , and Day 1 of Cycle 2 (each cycle is 28 days)

  2. Frequency of subjects with treatment-emergent adverse events

    Time frame: Assessed up to 28 days after study discontinuation

07

Study locations

28 sites
  • Aichi Cancer Center Hospital
    Nagoya, Aichi, Japan
  • Nagoya City University Hospital
    Nagoya, Aichi, Japan
  • Shikoku Cancer Center
    Matsuyama, Ehime, Japan
  • Kitakyushu Municipal Medical Center
    Kitakyushu, Fukuoka, Japan
  • Gunma Cancer Center
    Ota, Gunma, Japan
  • Hokkaido Cancer Center
    Sapporo, Hokkaido, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido, Japan
  • The Hospital of Hyogo College of Medicine
    Nishinomiya, Hyogo, Japan
  • Tsukuba University Hospital
    Tsukuba, Ibaraki, Japan
  • Tokai University Hospital
    Isehara, Kanagawa, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa, Japan
  • Nahanishi Clinic
    Naha, Okinawa, Japan
  • Kindai University Hospital
    Osakasayama, Osaka, Japan
  • Osaka University Hospital
    Suita, Osaka, Japan
  • Saitama Medical University International Medical Center
    Hidaka, Saitama, Japan
  • Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital
    Bunkyo, Tokyo, Japan
  • National Cancer Center Hospital
    Chuo, Tokyo, Japan
  • The Cancer Institute Hospital of JFCR
    Koto, Tokyo, Japan
  • Toranomon Hospital
    Minato, Tokyo, Japan
  • Showa University Hospital
    Shinagawa, Tokyo, Japan
  • Chiba Cancer Center
    Chiba, Japan
  • Kyushu Cancer Center
    Fukuoka, Japan
  • Sagara Hospital
    Kagoshima, Japan
  • Kumamoto University Hospital
    Kumamoto, Japan
  • Kyoto University Hospital
    Kyoto, Japan
  • Niigata Cancer Center Hospital
    Niigata, Japan
  • Okayama University Hospital
    Okayama, Japan
  • Osaka National Hospital
    Osaka, Japan
08

References and documents

Publications

  • Iwata H, Nakamura R, Masuda N, Yamashita T, Yamamoto Y, Kobayashi K, Tsurutani J, Iwasa T, Yonemori K, Tamura K, Aruga T, Tokunaga E, Kaneko K, Lee MJ, Yuno A, Kawabata A, Seike T, Kaneda A, Nishimura Y, Trepel JB, Saji S. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. Jpn J Clin Oncol. 2023 Jan 6;53(1):4-15. doi: 10.1093/jjco/hyac166. PubMed 36398439 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Apr 2019, 18 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 18 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 25, 2017
StartActual
Sep 22, 2017
Primary completionActual
Apr 4, 2019
CompletionActual
Mar 26, 2021
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03291886
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Sep 22, 2017
Primary completion
Apr 4, 2019
Completion
Mar 26, 2021
Last update
Jun 21, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entinostat

Start the discussion